Healthcare Disparity Efforts: Some Doubts, Stronger Incentives Needed | Managed Healthcare Executive® State of the Industry Survey
Survey shows some support but also some doubt about how effective the efforts will be. A sizable minority (43%) of respondents indicated that they believe stronger incentives are needed.
The combination of the uneven effects of COVID-19 pandemic and the killing of George Floyd put a spotlight on healthcare disparities in 2020. Almost every organization in U.S. healthcare rushed to address the issue in some way.
Responses to the Managed Healthcare Executive® annual State of the Survey showed support for the efforts. Only a small minority (13%) of the 450 respondents indicated that they agreed with the statement that the “underlying causes are too fundamental for healthcare to take on” and more than one-third (36%) agreed that addressing healthcare disparities is a good investment in dealing with the causes of health and illness.
However, the survey also revealed some doubts and belief that changes are needed. Nearlyhalf (47%) of the respondents indicated that they agree that efforts to address healthcare disparities are “well intentioned but unlikely to have a substantial effect.”A slightly smaller proportion (43%) said that financial incentives need to be strong to make them effective.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
